Clinical Trial

A Study of GC201 TIL in Advanced Gynecologic Tumors (10hospital)

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
This study is to investigate the safety and efficacy of signal switch receptor modified TIL (GC201 TIL) in patients with advanced gynecologic tumors. Autologous TILs from tumor resections or biopsies are first gene modified(TGF-β receptor or PD-1 gene modified TILs which could transfer the suppression signal surrounding the microenvironment of tumor bed into persistent T cell activation signal) and than expanded before i.v. infusion into the patient after NMA lymphodepletion treatment with hydroxychloroquine(600mg,single-dose) and cyclophosphamide.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2021-10-26; most recent amendment 2025-12-04.
Trial Details
NCT Number NCT05098171
Lead Sponsor Shanghai Juncell Therapeutics
Collaborators: Shanghai 10th People's Hospital
Conditions Advanced Gynecologic Tumors, Signal Switch Receptor Modified TIL, Treatment Side Effects, Effects of Immunotherapy
Enrollment 50 participants
Start Date 2021-09-26
Primary Completion 2026-09-25 (estimated)
Study Completion 2027-09-25 (estimated)
Updated on ClinicalTrials.gov 2025-12-11